We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Luke
Emrich-Mills
luke.emrich-mills.19@ucl.ac.uk
Dr
Dennis
Chan
dennis.chan@ucl.ac.uk
Dr
Dennis
Chan
dennis.chan@ucl.ac.uk
Other degenerative diseases of the nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This study aims to improve our ability to diagnose Alzheimer’s disease (AD) in its earliest stages. It will do so by using virtual reality (VR) technology to measure the functions of the entorhinal cortex (EC). The EC is the first part of the brain to show degeneration in AD and so EC-based tests may have superior diagnostic accuracy to tests currently used in clinical practice.
This study builds on our previous work showing a VR navigation task, assessing one function of the EC, has higher diagnostic accuracy than a number of gold standard memory tests used to diagnose early AD. in this second stage study we will test a larger number of people and will also include people in even earlier stages of AD, not just prior the onset of dementia but even before the onset of mild cognitive impairment. We will also use additional VR tests of memory for objects, assessing other EC functions beyond navigation, in order to enhance diagnostic value.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
1. Presence of significant cerebrovascular disease 2. Major medical co-morbidities 3. Major psychiatric disorder 4. The diagnosis of dementia 5. The presence of a treatable and/or reversible cause of cognitive impairment 6. Visual impairment sufficient to compromise the ability to perceive the study tasks 7. An inability to follow the verbal and written study instructions, due to communication needs or language barriers
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Dennis
Chan
dennis.chan@ucl.ac.uk
Luke
Emrich-Mills
luke.emrich-mills.19@ucl.ac.uk
Dr
Dennis
Chan
dennis.chan@ucl.ac.uk
The study is sponsored by University College London and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 50015
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
